Incidence and Risk Factors of Colistin-Induced Nephrotoxicity Associated with The International Consensus Guidelines for the Optimal Use of the Polymyxins: A Retrospective Study in a Tertiary Care Hospital, Saudi Arabia

Fawaz M. Alotaibi 1,*, Bashayer M. Alshehail 1, Zainab A. H. Al Jamea 2, Royes Joseph 1, Amal H. Alanazi 3, Najla A. Alhamed 3 and Reyouf S. Alqarni 3

Abstract: Background: Colistin is an effective therapy against multidrug-resistant gram-negative bacteria. However, nephrotoxicity is a major issue with its use. Objective: We aimed to evaluate the incidence and the potential risk factors of nephrotoxicity in colistin-treated patients. Methods: A retrospective cohort study was conducted. All adult patients aged 18 years and older who received colistin for \( \geq 72 \) h were included in the study, while end-stage kidney disease patients requiring dialysis or had renal transplants were excluded. The incidence and severity of acute kidney injury (AKI) were assessed based on the Kidney Disease Improving Global Outcomes (KDIGO). Result: Out of 128 patients who received colistin, 51.56% of them have experienced AKI. The incidence was increased among oldest patients (above 80) and those who did not receive the appropriate dose (\( p \)-value = 0.0003). In addition, the median time until the AKI occurred was 10 days after receiving the colistin treatment. Rates of AKI in patients with previous AKI (71.7%) were three times higher than patients who did not previously experience AKI (HR = 2.97, 95% CI [1.8–4.8]). Conclusions: Nephrotoxicity is a significant issue among patients who receive colistin in the hospital, especially among older patients and those who did not receive the appropriate dose. As a result, healthcare providers should play a major role in colistin dosing, especially among the older adult population.

Keywords: nephrotoxicity; antibacterial; adverse drug reactions; colistin; retrospective study; pharmacoepidemiology

1. Introduction

Steadily increasing antibiotic resistance is a universal public health threat [1–3]. Of particular concern is the alarming increase in the prevalence of multi-drug and extensively-drug resistant gram-negative organisms among nosocomial-acquired infections. The gram-negative microorganisms of major concern are *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae* [2–7]. The wide spread of MDR limits the choices of effective antibiotics against these organisms, which increases the complexity of the treatment plan [2,8]. Consequently, colistin has been re-adopted in the early 2000s as a core salvage therapy to tackle the deleterious influence of these infections [2,4,6,8–10].

Colistin (polymyxin E) is a naturally isolated antibiotic that was discovered in 1950. However, the role of colistin as a therapeutic option decreased in the 1970s as it was associated with nephrotoxicity, and antibiotic agents with improved safety profiles have become readily available [5,7,8,11–14]. Several studies have shown that colistin effectively...
treats multidrug-resistant gram-negative organisms. However, the cure and mortality rates have been reported as 75% and 60%, respectively [1,7,15,16].

Colistin-induced nephrotoxicity remains the major dose-limiting adverse event associated with its use [14] and although its efficacy has been well established for decades, the incidence rate of AKI, the time-to-AKI, and the potential predisposing factors have not been well-defined yet [9]. The incidence of colistin-induced AKI was reported to be between 20–60% [4,14,17]. This heterogeneity between studies could be attributed to using various definitions of AKI, the inclusion of different patient populations, and the use of a wide range of dosing regimens of colistin [14,17–19]. The time-to-incidence of acute kidney injury in patients treated with colistin has been shown to range between 5–12 days [4–6,9,19]; nephrotoxicity is usually reversible upon dose modification or treatment cessation [5,6]. Various colistin-associated AKI risk factors have been reported, including the prolonged duration of colistin therapy [14,17], coadministration of nephrotoxic agents [4,14,17,20–22], advanced age [4,6,17,23,24], higher weight independent of the dose [17], underlying disease severity [4], baseline renal function [5,6], hypoalbuminemia [4,17], high Charlson Comorbidity index score (CCI score) [4,25], and chronic comorbidities such as diabetes mellitus, chronic obstructive pulmonary disease, chronic liver disease, and hypertension [5,17,22].

Since the launch of the new International Consensus Guidelines for Optimal Use of Polymyxins in early 2019, a limited number of studies has been published to assess the incidence rate of AKI and the predisposing risk factors in light of these newly recommended doses [14]. Hence, an expanded view on these factors is of particular importance. Moreover, positive health-related outcomes might be achieved once the effect of the potentially modifiable predisposing factors for AKI in colistin-treated patients is mitigated. Thus, well-defined risk factors are warranted.

As a great paucity exists in the literature published in this area on global and national levels, this study was conducted to evaluate the incidence and potential predisposing risk factors for acute kidney injury among patients treated with colistin, considering the newly recommended doses.

2. Methods

**Study Design and Setting:** This was a retrospective study of patients treated with colistin at a tertiary care hospital, King Fahad Hospital of the University (KFHU) in the Eastern Province, Saudi Arabia. KFHU is a teaching and referral hospital with a 550 bed capacity.

**Study Participants:** Patients were included if they were 18 years of age and older, received colistin for ≥72 h for a documented resistant gram-negative bacterial infection, and had daily serum creatinine monitoring. In addition, patients with end-stage renal disease (ESRD), who required any form of renal replacement therapy (RRT) at the time of colistin initiation, or renal transplant patients were excluded. For patients who received more than one course of colistin, only the first course was included in the analysis. The informatics department generated a list of all patients who received colistin between January 2019 and June 2021.

**Study Outcomes:** The primary outcome of the study is the incidence of AKI among colistin-treated patients and the predisposing risk factors were considered as secondary outcomes. The incidence of AKI was assessed based on the KDIGO guideline definition. The KDIGO Clinical Practice Guidelines for Acute Kidney Injury define AKI as an increase in serum creatinine (SCr) by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 h, or an increase in SCr ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days, or a urine volume <0.5 mL/kg/h for 6 h [24]. Due to the retrospective nature of the present study, the urine volume was not assessed as the urinary output-related information might potentially be unavailable.

**Data Collection:** A standardized data collection form that is constructed of three main domains; patient-related variables, admission-related variables, and therapeutic management-related variables was utilized for collecting the data from patients’ medical records using the hospital’s computerized system (QuadraMed® Plano, Plano, TX, USA).
All the data we have received from the informatics department were deidentified data to protect patient confidentiality according to IAU-IRB’s policy.

The first domain was designed to collect patient-related information that includes patient demographics (i.e., age, gender, weight, and BMI), comorbidities (i.e., diabetes mellitus, hypertension, heart failure, chronic kidney disease, cancer, and others), Charlson comorbidity index score, and renal function (i.e., baseline renal function “Scr and estimated creatinine clearance (eCrCl), which was calculated based on Cockcroft and Gault formula”, previous acute kidney injury, AKI after colistin therapy, degree of severity of AKI, and reversibility of AKI).

The second domain contains admission-related information such as the level of care (i.e., critical versus non-critical), number of days of hospital stay, and recent hospital admissions within the previous 90 days.

Lastly, the therapeutic management-related information domain was incorporated three major parts: colistin-related information (i.e., dose of intravenous colistin per day, total daily dose if more than one route of administration was utilized, total cumulative dose of colistin, duration of colistin therapy in days, and appropriateness of the dose), concomitant therapies (i.e., antimicrobials and non-antimicrobial therapy), and microbiological data (i.e., site of infection and causative micro-organism). Appropriateness of each medication/dose was assessed by a team of clinical pharmacists specialized in infectious diseases and critical care patients.

Statistical Analysis: Data were summarized through mean and standard deviation (SD) for continuous variables and frequency and percentage for categorical variables. The time to the incidence of AKI was calculated as the time difference in days between administration of colistin and the incidence of AKI. The median incidence time and incidence rate were estimated using the Kaplan–Meier curve. The Cox proportional hazards model was used to examine the association between the incidence time and the set of predictor variables. The Hazard Ratio (HR) was measured to identify risk factors for the occurrence of the incidence of AKI. We estimated HRs with a 95% Confidence Interval (CI) in adjusted and unadjusted regression models. Variables found significant in unadjusted models or with theoretical importance were included in the adjusted model, where the interaction effect was also examined. Missing data were assumed missing at random for the regression models. Multiple imputation using chained equations was performed to create 60 complete datasets with 10 initial burn-in iterations [26]. The imputed variables (% of missing data) were BMI (21.9%), CCI (6.3%), DM (10.9%), HTN (7%), eCrCl (5.5%), previous AKI (1.6%), previous hospitalization (1.6%), inotropic support (9.4%), CRRT (9.4%), appropriateness of the dose (6.3%), loop diuretics (0.8%), NSAIDs (0.8%), A Baumannii (0.8%), and K Pneumoniae (0.8%). The imputation models included all covariates in the estimation model, AKI event indicator, and the corresponding Nelson–Aalen estimator of the cumulative hazard (White and Royston, 2009). Results with p-values less than 0.05 were considered statistically significant. All analyses were performed using Stata/SE 16.1 [27].

Ethical considerations: The study received approval from the Deanship of Scientific Research at Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia (IRB number: IRB-UGS-2021-5-085). Informed consent was not obtained from the participants given the retrospective nature of the study.

3. Results
3.1. Baseline Characteristics of the Study Population

One hundred and twenty-eight patients met the inclusion criteria, and their baseline characteristics are presented in Table 1. Among the included participants, 45 (35.2%) were older adult (older than 65 years), 81 (63.3%) were males, 65 (50.8%) had a BMI > 25 kg/m², 69 (53.9%) with DM, 69 (53.9%) with HTN, and 71 (55.8%) with moderate-severe CCI. Further, 46 patients (35.9%) had a previous history of AKI, 42 (32.8%) had a previous hospital admission within the past 90 days, 56 (43.8%) were on inotropic support, and 15 (11.7%) received CRRT. Importantly, 52 (40.6%) had inappropriate colistin doses. Vancomycin,
Meropenem, and NSAIDs were co-administered with colistin on 33 (26.0%), 79 (62.2%), and 29 (22.7%) patients, respectively.

**Table 1.** Baseline characteristics of study patients and incidence of AKI.

| Variables                        | Total n (%) | Incidence n (%) | Unadjusted HR * (95% CI) | p-Value ** |
|----------------------------------|-------------|-----------------|--------------------------|------------|
| **Age (in years)**               |             |                 |                          |            |
| 24–45                            | 36 (28.1%)  | 10 (27.8%)      | ref.                     |            |
| 46–65                            | 47 (36.7%)  | 26 (55.3%)      | 3.39 (1.62–7.12)         | 0.001      |
| 66–80                            | 18 (14.1%)  | 10 (55.6%)      | 3.60 (1.48–8.77)         | 0.005      |
| above 80                         | 27 (21.1%)  | 20 (74.1%)      | 4.17 (1.93–9.01)         | 0.000      |
| **Gender**                       |             |                 |                          |            |
| F                                | 47 (36.7%)  | 23 (48.9%)      | ref.                     |            |
| M                                | 81 (63.3%)  | 43 (53.1%)      | 1.01 (0.61–1.68)         | 0.972      |
| **BMI**                          |             |                 |                          |            |
| <25                              | 35 (27.3%)  | 18 (51.4%)      | ref.                     |            |
| 25–29.9                          | 36 (28.1%)  | 21 (58.3%)      | 1.28 (0.66–2.46)         | 0.467      |
| 30 or above                      | 29 (22.7%)  | 18 (62.1%)      | 1.17 (0.6–2.28)          | 0.643      |
| **DM**                           |             |                 |                          |            |
| No                               | 45 (35.2%)  | 15 (33.3%)      | ref.                     |            |
| Yes                              | 69 (53.9%)  | 43 (62.3%)      | 2.51 (1.4–4.49)          | 0.002      |
| **HTN**                          |             |                 |                          |            |
| No                               | 50 (39.1%)  | 20 (40%)        | ref.                     |            |
| Yes                              | 69 (53.9%)  | 42 (60.9%)      | 2.0 (1.17–3.42)          | 0.012      |
| **Charlson Comorbidity index (CCI)** |      |                 |                          |            |
| mean (SD)                        | 3 (3)       | 3 (2) vs. 4 (3) | 1.11 (1.02–1.21)         | 0.011      |
| No 0                             | 21 (16.4%)  | 7 (33.3%)       | ref.                     |            |
| Mild 1–2                         | 28 (21.9%)  | 13 (46.4%)      | 1.75 (0.73–4.21)         | 0.214      |
| Moderate 3–4                     | 31 (24.2%)  | 18 (58.1%)      | 2.13 (0.98–4.63)         | 0.055      |
| Severe 5 or above                | 40 (31.3%)  | 25 (62.5%)      | 2.74 (1.31–5.71)         | 0.007      |
| **eCrCl range**                  |             |                 |                          |            |
| 10–29                            | 8 (6.3%)    | 3 (37.5%)       | ref.                     |            |
| 30–49                            | 19 (14.8%)  | 16 (84.2%)      | 3.9 (1.13–13.49)         | 0.032      |
| 50–59                            | 12 (9.4%)   | 10 (83.3%)      | 3.39 (0.93–12.34)        | 0.064      |
| 60–79                            | 11 (8.6%)   | 3 (27.3%)       | 1.05 (0.21–5.16)         | 0.950      |
| ≥80                              | 71 (55.5%)  | 32 (45.1%)      | 1.25 (0.38–4.06)         | 0.715      |
| **Previous AKI**                 |             |                 |                          |            |
| No                               | 80 (62.5%)  | 31 (38.8%)      | ref.                     |            |
| Yes                              | 46 (35.9%)  | 33 (71.7%)      | 2.93 (1.78–4.8)          | 0.000      |
| **Recent hospital admission within 90 days** | | | | |
| No                               | 84 (65.6%)  | 35 (41.7%)      | ref.                     |            |
| Yes                              | 42 (32.8%)  | 29 (69%)        | 1.71 (1.04–2.79)         | 0.033      |
| **Level of care**                |             |                 |                          |            |
| Critical                         | 101 (79%)   | 53 (52.48)      | ref.                     |            |
| Non-critical                     | 25 (19%)    | 12 (52.17)      | 0.619 (0.145–2.642)      | 0.4839     |
| **Length of hospitalization**    |             |                 |                          |            |
| Mean (SD)                        | 70 days (61) | 80 (67) vs. 58 (53) | 0.998 (0.995–1.000)     | 0.2005     |
| **Duration of therapy with Colistin** |         |                 |                          |            |
| Mean (SD)                        | 12 (7.8)    | 14 (8) vs. 10 (8) | 0.966 (0.940–0.993)      | 0.0144     |
| **Inotropic Support**            |             |                 |                          |            |
| No                               | 60 (46.9%)  | 25 (41.7%)      | ref.                     |            |
| Yes                              | 56 (43.8%)  | 38 (67.9%)      | 1.82 (1.09–3.03)         | 0.022      |
| **CRRT**                         |             |                 |                          |            |
| No                               | 101 (78.9%) | 50 (49.5%)      | ref.                     |            |
| Yes                              | 15 (11.7%)  | 13 (86.7%)      | 2.55 (1.33–4.91)         | 0.005      |
Table 1. Cont.

| Variables                  | Total n (%) | Incidence n (%) | Unadjusted HR * (95% CI) | p-Value ** |
|----------------------------|-------------|-----------------|--------------------------|------------|
| Appropriateness of the dose|             |                 |                          |            |
| No                         | 52 (40.6%)  | 34 (65.4%)      | ref.                     |            |
| Yes                        | 68 (53.1%)  | 29 (42.6%)      | 0.44 (0.27–0.73)         | 0.001      |
| Loop diuretics             |             |                 |                          |            |
| No                         | 70 (54.7%)  | 32 (45.7%)      | ref.                     |            |
| Yes                        | 57 (44.5%)  | 34 (59.6%)      | 1.82 (1.11–2.99)         | 0.018      |
| NSAIDs                     |             |                 |                          |            |
| No                         | 98 (76.6%)  | 46 (46.9%)      | ref.                     |            |
| Yes                        | 29 (22.7%)  | 20 (69%)        | 2.2 (1.3–3.75)           | 0.004      |
| Vancomycin                 |             |                 |                          |            |
| No                         | 94 (74.0%)  | 48 (51.1%)      | ref.                     |            |
| Yes                        | 33 (26.0%)  | 18 (54.6%)      | 1.03 (0.59–1.77)         | 0.928      |
| Meropenem                  |             |                 |                          |            |
| No                         | 48 (37.8%)  | 29 (60.4%)      | ref.                     |            |
| Yes                        | 79 (62.2%)  | 37 (46.8%)      | 0.63 (0.39–1.04)         | 0.071      |
| UTI Infection              |             |                 |                          |            |
| No                         | 68 (53.1%)  | 31 (45.6%)      | ref.                     |            |
| Yes                        | 59 (46.1%)  | 35 (59.3%)      | 1.33 (0.82–2.17)         | 0.245      |
| Pneumonia Infection        |             |                 |                          |            |
| No                         | 34 (26.5)   | 17 (50)         | ref.                     |            |
| Yes                        | 93 (72.66)  | 49 (52.69)      | 0.928 (0.625–1.378)      | 0.7125     |
| Wound Infection            |             |                 |                          |            |
| No                         | 88 (68.75)  | 39 (44.32)      | ref.                     |            |
| Yes                        | 39 (30.47)  | 27 (70)         | 0.628 (0.425–0.929)      | 0.019      |
| Bacteremia                 |             |                 |                          |            |
| No                         | 50 (39.37)  | 24 (48)         | ref.                     |            |
| Yes                        | 77 (60.63)  | 42 (54.55)      | 0.971 (0.678–1.390)      | 0.8717     |
| A Baumannii                |             |                 |                          |            |
| No                         | 31 (24.2%)  | 13 (41.9%)      | ref.                     |            |
| Yes                        | 96 (75%)    | 53 (55.2%)      | 1.0 (0.54–1.85)          | 0.989      |
| K Pneumoniae               |             |                 |                          |            |
| No                         | 59 (46.1%)  | 26 (44.1%)      | ref.                     |            |
| Yes                        | 68 (53.1%)  | 40 (58.8%)      | 1.36 (0.83–2.23)         | 0.223      |
| Albumin level              | mean (SD)†  |                 |                          |            |
| No                         | 2.64 (0.6)  | 2.71 (0.6) vs. 2.57 (0.7) | 0.87 (0.58–1.31) | 0.516      |
| Yes                        | 9 (5)       | 9 (5) vs. 9 (5) | 1.0 (0.95–1.04)          | 0.856      |

1 mean (SD) of variables for non-AKI vs AKI patients. * Unadjusted Hazard Ratio. ** p-Value considered significant at 0.05. ref = reference group.

3.2. Incidence of AKI

Sixty-six (51.6%) patients had AKI during the hospitalization following colistin administration with an incidence rate of 6.41 per 100 person-days. The median incidence time was 10 days (95% CI: 8 to 14 days) (Figure 1). Regarding the severity of AKI, 14 (21.2%), 19 (28.8%), and 33 (50.0%) were on stage 1, 2, and 3, respectively. In addition, more than half of our population had experienced reversible AKI, which occurred in 37 (56.1%) patients.
more than half of our population had experienced reversible AKI, which occurred in 37 (56.1%) patients.

Figure 1. Kaplan–Meier curve for the incidence of AKI among colistin-treated patients.

3.3. Predictors of AKI

The number of incident cases in each level of prognostic factors are presented in Table 1. The unadjusted regression model showed that older adults, DM, HTN, higher CCI score, history of AKI, previous hospitalization in the past six months, inotropic support, CRRT, and patients on loop diuretics or NSAIDs were significantly associated with the higher incidence of AKI. Importantly, patients with an appropriate dose of colistin had a significantly reduced risk of AKI \([\text{unadjusted HR: } 0.44 (0.27–0.73)]\). Table 2 presents the adjusted HR with (95% CI) for the occurrence of AKI. The model showed a statistically significant interaction effect between age and CCI, which indicates differential effect of CCI on risk of AKI within age groups. Further, age, eCrCl, history of AKI incidence, Inotropic support, CRRT, and NSAIDs were significantly associated with the increased risk of AKI. Although the rate of AKI decreased when the patients received an appropriate colistin dose, the association was not statistically significant.

Table 2. Predictors of occurrence of AKI—adjusted model.

| Variables                  | Adjusted HR (95% CI) * | p-Value ** |
|----------------------------|------------------------|------------|
| Age                        |                        |            |
| 24–45                      | 7.72 (1.88–31.68)      | 0.005      |
| 46–65                      | 1.47 (0.13–16.27)      | 0.751      |
| 66–80                      | 7.01 (0.99–49.71)      | 0.051      |
| above 80                   |                        |            |
| Interaction between Age & CCI | 1.21 (0.71–2.08)     | 0.481      |
| 24–45#CCI                  | 0.58 (0.4–0.85)        | 0.005      |
| 46–65#CCI                  | 0.93 (0.61–1.41)       | 0.732      |
| 66–80#CCI                  | 0.71 (0.54–0.94)       | 0.017      |
| above 80#CCI               |                        |            |
| DM                         |                        |            |
| No                         | 1.82 (0.85–3.92)       | 0.124      |
| Yes                        |                        |            |
Table 2. Cont.

| Variables                        | Adjusted HR (95% CI) * | p-Value ** |
|----------------------------------|------------------------|------------|
| HTN                              |                        |            |
| No                               | 1.4 (0.71–2.79)        | 0.334      |
| Yes                              |                        |            |
| eCrCl range                      |                        |            |
| 10–29                            | 4.34 (1–18.82)         | 0.050      |
| 30–49                            | 8.95 (1.74–46.03)      | 0.009      |
| 50–59                            | 1.11 (0.18–6.88)       | 0.914      |
| 60–79                            | 2.7 (0.48–15.32)       | 0.262      |
| ≥80                              |                        |            |
| Previous AKI                     |                        |            |
| No                               | 2.13 (1.03–4.41)       | 0.041      |
| Yes                              |                        |            |
| Recent hospital admission within 90 days | 1.24 (0.66–2.32) | 0.496      |
| Inotropic Support                |                        |            |
| No                               | 2.02 (1.05–3.88)       | 0.036      |
| Yes                              |                        |            |
| CRRT                             | 2.9 (1.25–6.73)        | 0.013      |
| appropriateness of the dose      |                        |            |
| No                               | 0.5 (0.16–1.55)        | 0.228      |
| Yes                              |                        |            |
| Loop diuretics                   |                        |            |
| No                               | 1.26 (0.69–2.28)       | 0.453      |
| Yes                              |                        |            |
| NSAIDs                           |                        |            |
| No                               | 2.57 (1.26–5.24)       | 0.009      |
| Yes                              |                        |            |
| Vancomycin                       | 0.99 (0.41–2.39)       | 0.979      |
| Yes                              |                        |            |
| Meropenem                        | 0.64 (0.32–1.27)       | 0.200      |

* Adjusted Hazard Ratio. ** p-Value considered significant at 0.05.

4. Discussion

Colistin dosing was standardized by the International Consensus Guidelines for the Optimal Use of the Polymyxins and endorsed by many infectious disease societies in 2019. The updated guideline is recommending higher doses than what was used previously, as lower doses are associated with treatment failure and resistance. The main concern with these doses is the safety profile in terms of nephrotoxicity. The primary objective of this retrospective study was to evaluate the incidence of AKI and its predisposing risk factors while using the updated recommendations. Based on our best knowledge, this is the first study in the region after the 2019 guidelines has been released. In this study, the incidence of colistin-induced nephrotoxicity was 51.6% among patients treated against multi-drug and extensively-drug resistant gram-negative organisms, which is approximately similar to previously reported studies (21–75%) [6,28,29]. While the consensus guidelines for the optimal use of polymyxins estimate nephrotoxicity rates of 20–50%, our findings suggested differently, and that could be related to differences and variability in AKI definition, patient population, and the presence of potential confounders such as concomitant use of other nephrotoxic agents [6,28,29].

Although this study was performed after the implementation of the updated guidelines, in our practice, half of the patients received inappropriate doses, and they experienced...
a higher incidence of AKI than those who received the updated dosing recommendation. This might be due to the variability in dose adjustments based on calculated creatinine clearance. Accordingly, this has highlighted the importance of developing an institution-based guild to aid healthcare providers in adjusting the doses and choosing the right dose and frequency.

A meta-analysis of randomized controlled trials compared the nephrotoxicity of colistin versus beta lactam-based regimens and showed that colistin had increased this risk by 140% [30]. However, the efficacy of colistin toward MDR gram-negative organisms outweighs the risk in some patients, and it is therefore used as an effective last line option. Our study confirmed that advanced age is a significant risk factor for AKI [6,8,15]. In addition, higher creatinine levels were observed in this age group as well. Previous research has highlighted the importance of monitoring renal function in older adult patients [29]. Moreover, in our population, the incidence of nephrotoxicity was greatly influenced by the need for ICU admission, CRRT, and the use of inotropes. The use of loop diuretics and NSAIDs also increase the risk of AKI, which is expected as those medications directly affect the kidney. Similar trends and risk factors have been observed in previously reported studies that were conducted in 2020 and 2021 [28,30]. Although our study had similar findings, we had the advantage to be able to use CCI to test the association with the severity of AKI. Our findings suggest that patients with high CCI score had a 50% increased risk of AKI incidence compared to other patients with lower CCI score. Thus, more emphasis should be put on patients with comorbidities and polypharmacy to avoid such complications.

There are several limitations related to our study. The first limitation is that our study is a retrospective and single-centre study, which limits the generalizability of the study results. The second limitation is the low sample size, which is insufficient to identify possible significant associations. However, there are strengths in our study, which is the first study conducted in the Eastern Province of KSA related to colistin-induced nephrotoxicity after the implementation of the consensus guidelines for the optimal use of polymyxins in 2019. In addition, our study considers one of the views that uses the KDIGO definition instead of RIFLE to determine colistin-induced nephrotoxicity. Such tools enhance the quality of our study by measuring the AKI correctly and more accurately compared to other available tools [31].

5. Conclusions

Colistin is one of the limited therapeutic options for the management of MDR gram-negative organisms in hospital settings. In this retrospective cohort study, nephrotoxicity (as defined by KDIGO criteria) occurred among 51.6% of treated patients. Nephrotoxicity is a prevalent issue among patients who received colistin treatment in our setting and has serious adverse effects. Colistin therapy should be accompanied by carefully monitored serum creatinine levels, modification of the dose according to renal function, and avoidance of co-administration of other nephrotoxic agents; this will decrease the potential of the nephrotoxic effect of this effective antibiotic. There are limited studies in the literature about colistin nephrotoxicity worldwide. Thus, more studies are required to support the significance of the incidence of nephrotoxicity and risk factors associated with colistin use, especially after the implementation of the new dosing regimens to provide insight on strategies that maximize target therapeutic outcomes and optimize patient safety.

Author Contributions: F.M.A., B.M.A. and Z.A.H.A.J. have conceptualized the research question and supervised the project. F.M.A. and R.J. have done the statistical analysis. N.A.A., R.S.A. and A.H.A. have collected the data, and cleaned. All authors have participated equally in writing, editing the manuscript, and responding to the reviewers. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Imam Abdulrahman Bin Faisal University (IRB number UGS-2021-05-085 on 04/03/2021).

Informed Consent Statement: Informed consent was not obtained from the participants given the retrospective nature of the study.

Data Availability Statement: All collected data for this study are published in this article.

Conflicts of Interest: There is no conflict of interest to be declared.

References
1. Karaikos, I.; Lagou, S.; Pontikis, K.; Rapti, V.; Poulatou, G. The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Front. Public Health 2019, 7, 151. [CrossRef]
2. Kengla, K.; Kongpakwattana, K.; Saokaew, S.; Apisarnthanarak, A.; Chaiyakunapruk, N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: A systematic review and network meta-analysis. J. Antimicrob. Chemother. 2018, 73, 22–32. [CrossRef]
3. Magiorakos, A.-P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [CrossRef]
4. Kim, E.J.; Kim, E.S. Exploring New Predictors of Colistin-Associated Nephrotoxicity. Infect. Chemother. 2018, 50, 283–285. [CrossRef]
5. Koksal, I.; Kaya, S.; Gencalioglu, E.; Yilmaz, G. Evaluation of Risk Factors for Intravenous Colistin Use-related Nephrotoxicity. Oman Med. J. 2016, 31, 318–321. [CrossRef]
6. Ozel, A.S.; Ergönül, Ö.; Korten, V. Colistin nephrotoxicity in critically ill patients after implementation of a new dosing strategy. J. Infect. Dev. Ctries. 2019, 13, 877–885. [CrossRef]
7. Zhang, H.; Zhang, Q. Clinical efficacy and safety of colistin treatment in patients with pulmonary infection caused by Pseudomonas aeruginosa or Acinetobacter baumannii: A meta-analysis. Arch. Med. Sci. AMS 2015, 11, 34–42. [CrossRef]
8. Özkarakaş, H.; Köse, İ.; Zincircioğlu, Ç.; Ersan, S.; Ersan, G.; Şenoğlu, N.; Köse, S.; Erbay, R.H. Risk factors for colistin-associated nephrotoxicity and mortality in critically ill patients. Turk. J. Med. Sci. 2017, 47, 1165–1172. [CrossRef]
9. Miano, T.A.; Lautenbach, E.; Wilson, F.P.; Guo, W.; Borovskiy, Y.; Hennessy, S. Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury. Clin. J. Am. Soc. Nephrol. 2018, 13, 542. [CrossRef]
10. Viehman, J.A.; Nguyen, M.H.; Doi, Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs 2014, 74, 1315–1333. [CrossRef]
11. Forrest, A.; Garonzik, S.M.; Thamlikitkul, V.; Giamarellos-Bourboulis, E.J.; Paterson, D.L.; Li, J.; Silveira, F.P.; Nation, R.L. Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients. Antimicrob. Agents Chemother. 2017, 61, e01367–17. [CrossRef]
12. Nation, R.L.; Li, J.J.; Cars, O.; Coutet, W.; Dudley, M.N.; Kaye, K.S.; Mouton, J.W.; Paterson, D.L.; Tam, V.H.; Theuretzbacher, U.; et al. Framework for optimisation of the clinical use of colistin and polymyxin B: The Prato polymyxin consensus. Lancet Infect. Dis. 2015, 15, 225–234. [CrossRef]
13. Sorfi, L.; Luque, S.; Grau, S.; Berenguer, N.; Segura, C.; Montero, M.M.; Álvarez-Lerma, F.; Knobel, H.; Benito, N.; Horcajada, J.P. Trough colistin plasma level is an independent risk factor for nephrotoxicity: A prospective observational cohort study. BMC Infect. Dis. 2013, 13, 380. [CrossRef]
14. Tsuji, B.T.; Pogue, J.M.; Zavascki, A.P.; Paul, M.; Daikos, G.L.; Forrest, A.; Giacobbe, D.R.; Viscoli, C.; Giamarellos, H.; Karaikos, I.; et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019, 39, 10–39.
15. Chen, Z.; Chen, Y.; Fang, Y.; Wang, X.; Chen, Y.; Qi, Q.; Huang, F.; Xiao, M. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci. Rep. 2015, 5, 17091. [CrossRef]
16. Ngamprasertchai, T.; Boonyasiri, A.; Charoenpong, L.; Nimitvila, S.; Lorchirachoonkul, N.; Wattanamongkonsil, L.; Thamlikitkul, V. Effectiveness and safety of polymyxin B for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria in Thailand. Infect. Drug Resist. 2018, 11, 1219–1224. [CrossRef]
17. Nation, R.L.; Rigatto, M.H.P.; Falci, D.R.; Zavascki, A.P. Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity. Antibiotics 2019, 8, 24. [CrossRef]
18. Gai, Z.; Samodelov, S.L.; Kullak-Ublick, G.A.; Visentin, M. Molecular Mechanisms of Colistin-Induced Nephrotoxicity. Molecules 2019, 24, 653. [CrossRef]
19. Shields, R.K.; Anand, R.; Clarke, L.G.; Paronish, J.A.; Weirich, M.; Perone, H.; Kieserman, J.; Freedy, H.; Andrzejewski, C.; Bonilla, H. Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. PLoS ONE 2017, 12, e0173286. [CrossRef]
20. Omrani, A.S.; Alfahad, W.A.; Shoukri, M.M.; Baadani, A.M.; Aldalbahi, S.; Almitwazi, A.A.; Albarrak, A.M. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. *Ann. Clin. Microbiol. Antimicrob.* 2015, 14, 3. [CrossRef]

21. Paul, M.; Daikos, G.L.; Durante-Mangoni, E.; Yahav, D.; Carmeli, Y.; Benattar, Y.D.; Skiada, A.; Andini, R.; Eliakim-Raz, N.; Nutman, A.; et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: An open-label, randomised controlled trial. *Lancet Infect. Dis.* 2018, 18, 391–400. [CrossRef]

22. Yun, B.; Azad, M.A.K.; Wang, J.; Nation, R.L.; Thompson, P.E.; Roberts, K.D.; Velkov, T.; Li, J. Imaging the distribution of polymyxins in the kidney. *J. Antimicrob. Chemother.* 2014, 70, 827–829. [CrossRef] [PubMed]

23. Oliota, A.F.; Penteado, S.T.; Tonin, F.S.; Fernandez-Llimos, F.; Sanches, A.C. Nephrotoxicity prevalence in patients treated with polymyxins: A systematic review with meta-analysis of observational studies. *Diagn. Microbiol. Infect. Dis.* 2019, 94, 41–49. [CrossRef] [PubMed]

24. Palevsky, P.M.; Liu, K.; Brophy, P.D.; Chawla, L.; Parikh, C.R.; Thakar, C.V.; Tolwani, A.J.; Waikar, S.S.; Weisbord, S.D. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Am. J. Kidney Dis.* 2013, 61, 649–672. [CrossRef] [PubMed]

25. Lodise, T.P.; Fan, W.; Griffith, D.C.; Dudley, M.N.; Sulham, K.A. A Retrospective Cohort Analysis Shows that Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure. *Antimicrob. Agents Chemother.* 2018, 62, e01165-17. [CrossRef]

26. White, I.R.; Royston, P.; Wood, A.M. Multiple imputation using chained equations: Issues and guidance for practice. *Stat. Med.* 2011, 30, 377–399. [CrossRef]

27. StataCorp. *Stata Statistical Software: Release 16*; StataCorp LLC: College Station, TX, USA, 2019.

28. Almutairy, R.; Aljarri, W.; Noor, A.; Elsamadisi, P.; Shamas, N.; Qureshi, M.; Ismail, S. Impact of Colistin Dosing on the Incidence of Nephrotoxicity in a Tertiary Care Hospital in Saudi Arabia. *Antibiotics* 2020, 9, 485. [CrossRef]

29. Temocin, F.; Erdinc, S.; Tulek, N.; Demirelli, M.; Bulut, C.; Ertem, G. Incidence and Risk Factors for Colistin-Associated Nephrotoxicity. *Jpn. J. Infect. Dis.* 2015, 68, 318–320. [CrossRef]

30. Al-Abdulkarim, D.A.; Alzuwayed, O.A.; Al Ammari, M.; Al Halwan, S.; Al Maklafi, N.; Thomas, A. Colistin-induced Nephrotoxicity in a Tertiary Teaching Hospital. *Saudi J. Kidney Dis. Transplant.* 2020, 31, 1057. [CrossRef]

31. Fan, H.C.; Chien, Y.S.; Jenq, C.C.; Tsai, M.H.; Fan, P.C.; Chang, C.H.; Chang, M.Y.; Tian, Y.C.; Fang, J.T.; Yang, C.W.; et al. Acute Kidney Injury Classification for Critically Ill Cirrhotic Patients: A Comparison of the KDIGO, AKIN, and RIFLE Classifications. *Sci. Rep.* 2016, 6, 23022. [CrossRef]